Diabetes

FDA Recall targets True Metrix blood glucose monitoring systems after E-5 errors risk mistreating diabetes; updated guidance helps patients, pharmacists prevent harm.

Integrated pharmacist-led care models help to improve diabetes outcomes, expand CGM use, and reduce costs through proactive, multidisciplinary patient management.

GLP-1 weight-loss drugs reshape healthcare and consumer spending, as markets surge, coverage splits, and subscription models spread.

FDA expands teplizumab to age 1 year for stage 2 type 1 diabetes—pharmacists must learn dosing, infusion logistics, and safety monitoring.

The interchangeable designation allows pharmacists to substitute Langlara for Lantus at the point of dispensing without prescriber intervention, a distinction that carries significant clinical and operational implications for pharmacy practice.

The FDA expands teplizumab-mzwv use to ages 1+ with stage 2 type 1 diabetes, detailing PETITE-T1D safety, EBV/CMV precautions, and pharmacist support to delay onset.

Extended data from ACHIEVE-4 reinforce the durability of oral GLP-1 receptor agonist therapy, with implications for long-term diabetes management and pharmacist-led care.

A postdischarge diabetes follow-up showed me how pharmacists prevent harm by catching omissions, simplifying plans, and using technology to restore patient confidence.

FDA approval expands teplizumab-mzwv to patients 1 year and older, helping delay type 1 diabetes onset for children with stage 2 diabetes.

New data highlight the impact of pharmacist-driven continuous glucose monitoring services on hemoglobin A1C reduction, time in range, and medication adherence.

Jennifer Goldman, PharmD, highlights clinical trial data and practical strategies for pharmacists to support initiation, adherence, and adverse effect management with tirzepatide at the American Pharmacists Association Annual Meeting and Exposition.

The first-in-class triple agonist met all primary and key secondary end points in the TRANSCEND-T2D-1 trial.

Clinical pharmacist specialists emphasized the pharmacist's role closing the gap between guideline recommendations and patient access to CGMs and automated insulin delivery.

Insulin icodec-abae injection becomes the first and only once-weekly basal insulin option, offering personalized care for adults with type 2 diabetes (T2D).

Swapping 30 minutes of teen sedentary time for vigorous activity or extra sleep cuts insulin resistance by 15%, aiding type 2 diabetes (T2D) prevention.

In patients with diabetes, liver stiffness testing flags hidden MASLD fibrosis and sharply higher death risk.

Mass-produced compounded GLP-1 drugs bypass FDA safeguards, raising sterility, quality, and supply-chain risks—putting patients at risk despite ending shortages.

This case report highlights pharmacists’ collaborative role in optimizing care transitions and diabetes management for a patient newly diagnosed with latent autoimmune diabetes in adults.

A large observational study identifies U-shaped relationship between weekday sleep duration and estimated glucose disposal rate.

Adherence to glucose-lowering drugs ranges from 41% to 68% depending on drug class.

Meta-analysis finds insulin efsitora provides similar glycemic control with superior hemoglobin A1C reduction at 52 weeks and lower total weekly insulin dose, while maintaining an acceptable safety profile.

WHO’s 2025 pregnancy diabetes guidance explains glucose monitoring, hemoglobin A1C targets, and metformin/insulin choices, with a focus on low-resource care.

Orforglipron, an oral GLP-1 medication, demonstrated superior weight loss and blood glucose control compared with oral semaglutide in patients with type 2 diabetes (T2D).

The oral solution improves central diabetes insipidus dosing precision, helping pharmacy teams tailor therapy, counsel patients, and monitor hyponatremia.

Preventing progression from prediabetes to type 2 diabetes improves patient outcomes while substantially reducing health system greenhouse gas emissions.